A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
about
Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphomaThe treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approachUse of geriatric assessment for older adults in the oncology setting: a systematic review.Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients.Comprehensive geriatric assessment in the older cancer patient: coming of age in clinical cancer care.Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.Screening older cancer patients for a Comprehensive Geriatric Assessment: A comparison of three instruments.Examining five- and ten-year survival in older women with breast cancer using cancer-specific geriatric assessment.Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette studyTailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphomaClinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature reviewThe value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancerDevelopment of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients.Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.Management Strategies for Elderly Patients with Diffuse Large B-Cell LymphomaThe feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia.Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly.Follicular Lymphoma: The Management of Elderly Patient.Systemic therapies for metastatic renal cell carcinoma in older adults.Autologous transplant of follicular lymphoma in the era of rituximab.Rehabilitation of older cancer patients.Diagnostic choices and clinical outcomes in octogenarians and nonagenarians with iron-deficiency anemia in the Netherlands.Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review.Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future.High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL - comparative study.Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions.How to manage mantle cell lymphoma.Breast cancer in the elderly: which lessons have we learned?Four Distinct Health Profiles in Older Patients With Cancer: Latent Class Analysis of the Prospective ELCAPA Cohort.Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK).Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.Predictors of 1-Year Mortality in a Prospective Cohort of Elderly Patients With Cancer.Geriatric assessment is superior to oncologists' clinical judgement in identifying frailty.
P2860
Q27025860-968A53A2-6443-410B-993E-6486A4F5E341Q30235296-FA0E878C-CD5E-45E3-9E69-DE8BBCE8CCA4Q33824082-A9FB0555-30F9-4444-B366-4ED539EF0510Q33878770-2AD57082-87FB-47A9-981E-42F33B8943FFQ34360763-3643299D-77FE-4412-BECB-746C233FCD46Q34879258-E4B79612-CFB3-42D8-ADBB-F24C077307CEQ34968015-E1071694-EADC-412F-BEC8-D6FEB2DD7B8CQ35021464-ACECFA3B-FDFA-4C1A-AC74-2684FD35C547Q35174486-644DF0E1-954D-47BA-A58F-9DBB01227331Q35214123-8662953D-6216-4351-9102-C3576BAD10B9Q35387511-45FDA097-9B14-42A2-969F-FE529CF6D812Q35807965-12230D50-9135-4136-B594-D11F590FBD80Q35989968-6905440A-4729-4055-8407-C1BBDDEE0261Q36051526-A1EC0B7D-A1AB-43FA-A9CC-95678090E59DQ36081242-874C1D96-35E7-4749-A5D6-1953D85C75B7Q36405665-5E9A15B2-1150-4DDC-966E-A60AE051F38DQ36789292-0DBAACC0-2C2F-417F-963A-57DB25167262Q36879957-94D6F5A7-CD1B-46CF-9729-89FC335367F8Q36949798-BB677842-9D45-44ED-A07D-8B9257594C90Q37195803-47EF330C-C8AB-4BF0-816F-1C73A526B91BQ37570641-AA4CC614-3511-4D36-ACA0-3FE94684935EQ37577856-6345348B-9F14-4655-BF0D-1A7DB41B3E48Q37677105-90F338F7-EADA-42C4-B601-0A42EC1CA57CQ37742624-246CA8F9-F350-4898-B043-B79B5A11035AQ38074193-FBB0BA21-F6BD-4D21-9B1B-A19E0C4D1C70Q38092183-CBC879FC-55FC-448C-98A5-7AE6C6D2C10DQ38378318-7C6E6298-E3EC-4FE1-ADC4-D95D23931A60Q38489690-EC729429-F17A-46DA-A5B2-5AA09B054D27Q38552083-3BAB9812-1582-4E11-B309-D59F4FB85724Q38614642-E7B450D4-3E5D-4B18-8F46-8CC91251B95FQ39144746-EB6292AF-A3B3-41A3-B877-3F4F93E41979Q39187610-924761ED-9874-4ABD-AD10-A55566D67C73Q39303318-3605FBC3-DF55-475C-B8F9-AFBBC4CE2A93Q39896359-0A6C1A94-8A6A-415D-AED7-0C0E5BD99596Q40095003-0D2FA3BD-EC21-40FF-8324-D9531C02F2A8Q40576636-C51E40DA-FA10-4F54-B9A1-044DB47D315AQ40590566-82C82FDD-19B5-428C-88A4-9BADD7D84EEFQ40831512-0DB48461-07A1-484B-8FFE-2A6CA378B313Q41124813-7E0A47A0-B32C-4112-B400-F9209CEE39B7Q41431242-EE5BD9DF-E847-49D3-9322-5B90FE5725F7
P2860
A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A comprehensive geriatric asse ...... nefit from aggressive therapy.
@en
A comprehensive geriatric asse ...... nefit from aggressive therapy.
@nl
type
label
A comprehensive geriatric asse ...... nefit from aggressive therapy.
@en
A comprehensive geriatric asse ...... nefit from aggressive therapy.
@nl
prefLabel
A comprehensive geriatric asse ...... nefit from aggressive therapy.
@en
A comprehensive geriatric asse ...... nefit from aggressive therapy.
@nl
P2093
P356
P1433
P1476
A comprehensive geriatric asse ...... enefit from aggressive therapy
@en
P2093
Alessandra Tucci
Chiara Bottelli
Erika Borlenghi
Monica Drera
Samantha Ferrari
P2860
P304
P356
10.1002/CNCR.24490
P407
P577
2009-10-01T00:00:00Z